Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.